Discontinued — last reported Q4 '25
Illumina Europe — Revenue increased by 14.2% to $353.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 8.3%, from $326.00M to $353.00M. Over 4 years (FY 2021 to FY 2025), Europe — Revenue shows an upward trend with a 2.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests growing market adoption or successful expansion of the installed base in Europe, while a decrease may signal increased competition, regulatory headwinds, or reduced research and clinical funding in the region.
This metric represents the total gross sales generated from products and services sold within the European geographic re...
Comparable to regional revenue reporting for other global life science tools and diagnostics companies, which typically segment performance by major geographic theaters to highlight regional growth trajectories.
ilmn_segment_europe_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $287.25M | $287.25M | $287.25M | $286.00M | $274.00M | $259.00M | $270.00M | $261.00M | $303.00M | $260.00M | $315.00M | $279.00M | $289.00M | $291.00M | $326.00M | $293.00M | $310.00M | $309.00M | $353.00M |
| QoQ Change | — | +0.0% | +0.0% | -0.4% | -4.2% | -5.5% | +4.2% | -3.3% | +16.1% | -14.2% | +21.2% | -11.4% | +3.6% | +0.7% | +12.0% | -10.1% | +5.8% | -0.3% | +14.2% |
| YoY Change | — | — | — | — | -4.6% | -9.8% | -6.0% | -8.7% | +10.6% | +0.4% | +16.7% | +6.9% | -4.6% | +11.9% | +3.5% | +5.0% | +7.3% | +6.2% | +8.3% |